HIV: The Cure’s Biggest Obstacle

Healthcare professional holding a swab next to a tray of sample vials

The scientific tools to eliminate HIV already exist, yet 39 million people worldwide remain infected, and the virus continues to spread—exposing a chasm between medical breakthroughs and the political will to deploy them.

Story Snapshot

The U.S. aims to reduce new HIV infections by 90% by 2030 through the Ending the HIV Epidemic initiative, targeting 57 high-need jurisdictions with coordinated federal funding
Gene-editing therapies and “induce and reduce” strategies represent potential functional cures, but the virus’s ability to hide in dormant cells remains the greatest scientific obstacle
While AIDS deaths have halved since 2005 and antiretroviral therapy transformed HIV into a manageable condition, only 44% of those on treatment achieve viral suppression
Federal authorities confirm elimination is theoretically achievable with existing tools, yet implementation gaps, funding shortfalls, and behavioral barriers prevent global scale-up

From Death Sentence to Chronic Condition

The HIV pandemic emerged in the 1980s as a medical catastrophe that killed with ruthless efficiency. Then came 1996 and the antiretroviral therapy revolution that transformed a death sentence into a chronic, manageable condition. Between 2005 and 2019, AIDS-related deaths were cut in half. By 2018, 19.5 million people—53% of those living with HIV globally—were receiving antiretroviral therapy. New diagnoses in the United States dropped 14% between 2010 and 2019, while viral suppression rates among Americans living with HIV climbed from 28% to 57% during the same period. Medical science delivered what seemed impossible four decades ago: the ability to live a normal lifespan with HIV.

The Latent Reservoir Problem

The virus hides. This biological reality represents the greatest obstacle to a permanent cure. HIV integrates into the DNA of CD4+ T-cells, creating dormant reservoirs that standard antiretroviral therapy cannot touch. Patients must take medication daily for life because stopping treatment allows the hidden virus to reactivate and replicate. ViiV Healthcare distinguishes between a “sterilizing cure”—complete viral elimination—and a “functional cure” where the body controls the virus without continuous treatment. Previous cure cases involved extreme cancer treatments requiring bone marrow transplants, procedures acknowledged as “not scalable to 39 million people across the globe.” The scientific community needs scalable solutions that work for populations, not individual medical miracles.

Gene Editing and Strategic Breakthroughs

The FDA granted fast-track designation to EBT-101 gene-editing therapy in July 2023, with clinical trials expected to conclude in March 2025. This represents the first potentially scalable curative approach beyond experimental case studies. Simultaneously, ViiV Healthcare advanced their “induce and reduce” strategy, publishing research in Nature demonstrating that IAP inhibitors can reactivate dormant HIV in animal models. The strategy maintains suppressive antiretroviral therapy to protect healthy cells while coaxing hidden virus out of hiding, where medications can eliminate it. These aren’t theoretical exercises—they’re concrete pathways toward functional cures that could work at population scale if funding and implementation follow.

America’s Concentrated Response

President Trump announced the Ending the HIV Epidemic initiative during his 2019 State of the Union address, setting an ambitious goal: reduce new infections by 90% by 2030. The federal government awarded $117 million in February 2020 to support implementation, focusing resources on 57 jurisdictions where transmission concentrates. The four-pillar approach—Diagnose, Treat, Prevent, Respond—recognizes that today’s epidemic consists of “diverse microepidemics with different underlying causes” requiring tailored local solutions rather than one-size-fits-all programs. The CDC confirms the 90% reduction goal is “achievable with sufficient resources.” That qualifier matters, because resources determine whether ambitious goals become reality or remain aspirational talking points.

The Undetectable Equals Untransmittable Revolution

Science delivered a prevention breakthrough that should have changed everything: people with HIV who achieve undetectable viral loads through consistent treatment cannot sexually transmit the virus. The U=U principle—Undetectable equals Untransmittable—transforms treatment into prevention. Viral suppression rates have improved, with more Americans living with HIV achieving undetectable status each year. Yet only 44% of those receiving antiretroviral therapy globally achieve viral suppression. The gap between medical capability and actual outcomes reveals the implementation crisis. Pills that prevent transmission only work when people take them consistently, access them affordably, and receive them without stigma or discrimination. The science works; the systems surrounding it often fail.

Global Disparities and Funding Realities

Approximately 39 million people live with HIV worldwide, concentrated disproportionately in low-income countries with limited healthcare infrastructure. The United Nations established Fast-Track Targets aiming for fewer than 500,000 new infections annually by 2020—a goal substantially missed. While high-income nations like the United States marshal concentrated resources for elimination efforts, global funding remains insufficient for universal scale-up. The pharmaceutical industry develops sophisticated cure strategies, but treatment access gaps persist even for existing therapies. A “cure gap” looms where wealthy populations access gene-editing treatments while others remain on older medication regimens. The National Institutes of Health acknowledges that theoretical elimination requires “additional and sustained resources to make available the already existing scientific advances on local, regional, national, and global levels.” Translation: we know how to end this pandemic, but we’re not funding it properly.

Behavioral and Social Barriers

Medical interventions encounter human realities. Stigma prevents people from seeking testing and treatment. Discrimination drives marginalized communities—men who have sex with men, transgender individuals, people who inject drugs, sex workers, incarcerated populations—away from healthcare systems. Poverty creates barriers to consistent medication access and adherence. Historical medical mistrust, particularly among communities subjected to exploitation and abuse by public health authorities, complicates outreach efforts. The virus concentrates in populations that face systematic obstacles to care. Federal authorities recognize these “behavioral and social determinants” as challenges potentially exceeding the scientific obstacles to cure development. You can’t treat people who won’t or can’t access treatment, regardless of how effective your medications are.

The 2030 Crossroads

Six years separate us from the Ending the HIV Epidemic initiative’s primary deadline. The United States aims for 90% reduction in new infections by 2030, with an interim 75% reduction target in 2025. Bipartisan Congressional support continues, federal funding flows to high-need jurisdictions, and scientific breakthroughs advance toward functional cures. The trajectory appears positive in well-resourced settings, but global elimination requires sustained international commitment that currently doesn’t exist at necessary scale. Experts across government, pharmaceutical, and public health sectors agree: elimination is theoretically achievable with current and near-future tools including a moderately effective HIV vaccine, optimal implementation of existing prevention and treatment strategies, and functional cure development. The question isn’t whether we can end the HIV epidemic—it’s whether we will allocate sufficient resources and political will to actually do it. Medical science answered its part of the challenge decades ago.